We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $139.37, moving +2.22% from the previous trading session. This move lagged the S&P 500's daily gain of 2.91%. Meanwhile, the Dow gained 2.49%, and the Nasdaq, a tech-heavy index, added 3.83%.
Shares of the HIV and hepatitis C drugmaker have depreciated by 9.12% over the course of the past month, outperforming the Medical sector's loss of 9.63%, and lagging the S&P 500's loss of 7.64%.
Analysts and investors alike will be keeping a close eye on the performance of Gilead Sciences in its upcoming earnings disclosure. The company is predicted to post an EPS of $1.86, indicating a 2.76% growth compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $6.86 billion, indicating a 2.93% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $8.66 per share and revenue of $30.18 billion, which would represent changes of +6.26% and +2.5%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Gilead Sciences. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Gilead Sciences currently has a Zacks Rank of #3 (Hold).
With respect to valuation, Gilead Sciences is currently being traded at a Forward P/E ratio of 15.75. This expresses a discount compared to the average Forward P/E of 17.84 of its industry.
It's also important to note that GILD currently trades at a PEG ratio of 1.79. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.49.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 148, putting it in the bottom 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $139.37, moving +2.22% from the previous trading session. This move lagged the S&P 500's daily gain of 2.91%. Meanwhile, the Dow gained 2.49%, and the Nasdaq, a tech-heavy index, added 3.83%.
Shares of the HIV and hepatitis C drugmaker have depreciated by 9.12% over the course of the past month, outperforming the Medical sector's loss of 9.63%, and lagging the S&P 500's loss of 7.64%.
Analysts and investors alike will be keeping a close eye on the performance of Gilead Sciences in its upcoming earnings disclosure. The company is predicted to post an EPS of $1.86, indicating a 2.76% growth compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $6.86 billion, indicating a 2.93% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $8.66 per share and revenue of $30.18 billion, which would represent changes of +6.26% and +2.5%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Gilead Sciences. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Gilead Sciences currently has a Zacks Rank of #3 (Hold).
With respect to valuation, Gilead Sciences is currently being traded at a Forward P/E ratio of 15.75. This expresses a discount compared to the average Forward P/E of 17.84 of its industry.
It's also important to note that GILD currently trades at a PEG ratio of 1.79. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.49.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 148, putting it in the bottom 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.